Screener
Alamar Biosciences ALMR Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Alamar Biosciences in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The source filing: Alamar Biosciences’s 10-Q, filed May 8, 2026.
- Filed
- May 8, 2026, 8:30 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-213424
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Accounts payable | 1,339 | 578 |
| Operating lease liabilities | (1,087) | (463) |
| Accrued expenses and other liabilities | (1,234) | (5,028) |
| Net cash used in operating activities | (20,347) | (13,068) |
| Cash flows from investing activities: | ||
| Maturities of short-term investments | — | 18,000 |
| Purchases of property and equipment | (600) | (554) |
| Capitalized software development costs | (178) | (428) |
Item 1. Financial Statements
FAQ
- What is Alamar Biosciences's operating cash flow?
- Alamar Biosciences (ALMR) reported operating cash flow of -$20.35M in Q1 2026.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.
Ask your AI about Alamar Biosciences's operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude